1 August 2019 - - US-based gene regulatory and immunotherapeutic drugs specialist Exicure, Inc.'s (OTCQB: XCUR) common stock will begin trading on the NASDAQ Capital Market under the symbol "XCUR" at the opening of trading on July 31, 2019, following its approval to list its common stock on the NASDAQ Capital Market, the company said.

Exicure also announced the pricing of the previously announced underwritten public offering of 27.5m shares of its common stock at a price to the public of USD 2.00 per share.

Exicure has also granted the underwriters a 30-day option to purchase up to an additional 4.125m shares of common stock to cover overallotments, if any.

The offering is expected to close on or about August 2, 2019 subject to customary closing conditions.

Exicure expects to receive gross proceeds of USD 55m from the sale of common stock in the offering, prior to deducting the underwriting discounts and commissions and estimated offering expenses payable by it.

Exicure intends to use the net proceeds from the offering to advance AST-008 through a Phase 1b/2 clinical trial; to develop an SNA therapeutic candidate for a neurology condition and advance it into Phase 1 clinical trials; and for general corporate purposes.

Guggenheim Securities is acting as sole book-running manager for the offering. Chardan is acting as lead manager for the offering. H.C. Wainwright and Co. and Ladenburg Thalmann are acting as co-managers for the offering.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology.

Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.

Exicure's lead programme is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.